BI
BMRN icon

Binnacle Investments’s BioMarin Pharmaceuticals BMRN Stock Holding History

Binnacle Investments’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$325 Buy
+6
New +$343 ﹤0.01% 889
2025
Q2 		– Sell
-6
Closed -$424 – 785
2025
Q1 		$424 Buy
+6
New +$404 ﹤0.01% 723

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Binnacle Investments's BMRN Position: Q3 2025 in Review

Binnacle Investments opened a new position in BioMarin Pharmaceuticals (BMRN) in Q3 2025: 6 shares worth $325. The stake represents ﹤0.01% of the portfolio and ranks #889 among its holdings. This is a return to the name: Binnacle Investments previously reported a position in BMRN as recently as Q1 2025.

Binnacle Investments first reported a position in BMRN in Q1 2025 and has held it in 2 quarters since. The position peaked at $424 in Q1 2025. 576 funds tracked by Wall St. Rank hold BMRN as of Q3 2025.

  • Binnacle Investments held 6 shares of BioMarin Pharmaceuticals worth $325 as of Q3 2025.
  • BioMarin Pharmaceuticals was a new Binnacle Investments position in Q3 2025.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Binnacle Investments's portfolio in Q3 2025, its #889 holding.
  • Binnacle Investments first reported a position in BioMarin Pharmaceuticals in Q1 2025 and has held it in 2 quarters since.
  • Binnacle Investments's BioMarin Pharmaceuticals position peaked at $424 in Q1 2025.
  • 576 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2025.

Based on Binnacle Investments's 13F filing for Q3 2025, filed 14 Nov 2025.